References
1.Abbott A. Are drugs for SARS on the horizon? Nature 2003;424:125-6.
2.Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 2003;300:1763-7. http://www.sciencemag.org/cgi/content/full/300/5626/1763
3.Baudouin S, Blumenthal S, Cooper B, et al. for the British Thoracic Society Standards of Care Committee. Non-invasive ventilation in acute respiratory failure. Thorax 2002;57:192-211. http://thorax.bmjjournals.com/cgi/content/full/57/3/192
4.Beijing Group of National Research Project for SARS. Dynamic changes in blood cytokine levels as clinical indicators in severe acute respiratory syndrome. Chin Med J 2003;116:1283-7. http://sarsreference.com/lit.php?id=14527349
5.Booth CM, Matukas LM, Tomlison GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003;289:2801-9. http://SARSReference.com/lit.php?id=12734147
6.Cameron MJ, Gold W, Dresser L, et al. Identification of gene expression profiles in patients with severe acute respiratory syndrome (SARS) that may be predictive of diagnosis, severity and clinical outcome of the illness [Abstract]. 43rd Annual Interscience Conference of Antimicrobial Agents and Chemotherapy, USA. September 2003.
7.Centers for Disease Control and Prevention. Interim domestic guidance on the use of respirators to prevent transmission of SARS. May 6, 2003. http://www.cdc.gov/ncidod/sars/pdf/respirators-sars.pdf
8.Centers for Disease Control and Prevention. Interim domestic infection control precautions for aerosol-generating procedures on patients with severe acute respiratory syndrome (SARS). September 23, 2003. http://www.cdc.gov/ncidod/sars/pdf/aerosolinfectioncontrolsars.pdf
- April 8-10
- April 12
- June 6
- August 14
- September 8
- September 24
- References
- 30 Virology
- Discovery of the SARS Virus
- Initial Research
- Coronaviridae
- SARS Co-V
- Genome Sequence
- Antiviral Agents and Vaccines
- Antiviral Drugs
- Vaccines
- Outlook
- References
- Routes of Transmission
- Patient Factors in Transmission
- Asymptomatic Patients
- Symptomatic Patients
- The Unsuspected Patients
- High-Risk Activities
- Transmission during Quarantine
- Introduction
- Global Spread
- Hong Kong
- Other Countries
- Eradication
- Outlook
- Introduction
- International Coordination
- Management of SARS in the post-outbreak period
- National Measures
- Legislation
- Quarantine after Discharge
- Infection Control in Healthcare Settings
- General Measures
- Protective Measures
- Special Settings
- Intensive Care Units
- Intubating a SARS Patient
- Anesthesia
- Triage
- Internet Sources
- After the Outbreak
- Conclusion
- 108 Case Definition
- WHO Case Definition
- Suspect case
- Reclassification of cases
- CDC Case Definition
- 112 Diagnostic Tests
- Introduction
- Laboratory tests
- Virus isolation
- Antibody detection
- Interpretation
- Limitations
- Biosafety considerations
- Clinical Presentation and Diagnosis
- Clinical Presentation
- Diagnosis
- Clinical Course
- Histopathology
- Lung Biopsy
- Postmortem Findings
- Discharge and Follow-up
- Psychosocial Issues
- References
- 144 SARS Treatment
- Antibiotic therapy
- Antiviral therapy
- Ribavirin
- Alternative medicine
- Immunomodulatory therapy
- Other immunomodulators
- Assisted ventilation
- Invasive mechanical ventilation
- Clinical outcomes
- Appendix 1
- A standardized treatment protocol for adult SARS in Hong Kong
- Appendix 2
- A treatment regimen for SARS in Guangzhou, China
- References
- 168 Pediatric SARS
- Clinical Manifestation